KCS Wealth Advisory Has $282,000 Stake in Johnson & Johnson (NYSE:JNJ)

Share on StockTwits

KCS Wealth Advisory trimmed its position in shares of Johnson & Johnson (NYSE:JNJ) by 5.0% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,936 shares of the company’s stock after selling 102 shares during the period. KCS Wealth Advisory’s holdings in Johnson & Johnson were worth $282,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in JNJ. Phocas Financial Corp. grew its stake in Johnson & Johnson by 999,928.6% during the second quarter. Phocas Financial Corp. now owns 125,173,583 shares of the company’s stock worth $1,743,000 after buying an additional 125,161,066 shares in the last quarter. Nuveen Asset Management LLC grew its stake in Johnson & Johnson by 5,447.1% during the second quarter. Nuveen Asset Management LLC now owns 16,924,656 shares of the company’s stock worth $2,357,266,000 after buying an additional 16,619,550 shares in the last quarter. Johanson Financial Advisors Inc. grew its stake in Johnson & Johnson by 14,438.5% during the fourth quarter. Johanson Financial Advisors Inc. now owns 2,470,520 shares of the company’s stock worth $16,935,000 after buying an additional 2,453,527 shares in the last quarter. Price T Rowe Associates Inc. MD grew its stake in Johnson & Johnson by 11.9% during the second quarter. Price T Rowe Associates Inc. MD now owns 20,791,713 shares of the company’s stock worth $2,895,870,000 after buying an additional 2,204,757 shares in the last quarter. Finally, Vanguard Group Inc. boosted its stake in shares of Johnson & Johnson by 0.7% in the 2nd quarter. Vanguard Group Inc. now owns 225,158,988 shares of the company’s stock valued at $31,360,143,000 after purchasing an additional 1,627,370 shares in the last quarter. Hedge funds and other institutional investors own 67.28% of the company’s stock.

JNJ opened at $147.01 on Thursday. The company’s 50 day moving average is $143.07 and its 200-day moving average is $134.77. Johnson & Johnson has a 1-year low of $125.00 and a 1-year high of $147.84. The company has a current ratio of 1.26, a quick ratio of 1.00 and a debt-to-equity ratio of 0.46. The company has a market cap of $385.62 billion, a P/E ratio of 17.97, a PEG ratio of 2.36 and a beta of 0.71.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, October 15th. The company reported $2.12 EPS for the quarter, topping the consensus estimate of $2.00 by $0.12. Johnson & Johnson had a net margin of 21.09% and a return on equity of 39.81%. The business had revenue of $20.73 billion for the quarter, compared to the consensus estimate of $20.14 billion. During the same period last year, the company earned $2.05 EPS. The firm’s revenue was up 1.9% compared to the same quarter last year. On average, equities analysts forecast that Johnson & Johnson will post 8.66 EPS for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Tuesday, February 25th will be given a dividend of $0.95 per share. The ex-dividend date of this dividend is Monday, February 24th. This represents a $3.80 annualized dividend and a yield of 2.58%. Johnson & Johnson’s dividend payout ratio is presently 46.45%.

In related news, EVP Kathryn E. Wengel sold 2,017 shares of Johnson & Johnson stock in a transaction that occurred on Thursday, December 12th. The shares were sold at an average price of $141.07, for a total transaction of $284,538.19. Following the sale, the executive vice president now directly owns 51,736 shares in the company, valued at approximately $7,298,397.52. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Hubert Joly bought 5,000 shares of the business’s stock in a transaction that occurred on Friday, December 13th. The shares were acquired at an average price of $141.28 per share, for a total transaction of $706,400.00. Following the completion of the transaction, the director now owns 5,000 shares in the company, valued at $706,400. The disclosure for this purchase can be found here. 0.23% of the stock is owned by company insiders.

JNJ has been the topic of a number of research analyst reports. Atlantic Securities upgraded shares of Johnson & Johnson from an “underweight” rating to a “neutral” rating in a research note on Wednesday, October 16th. Credit Suisse Group restated a “buy” rating and issued a $163.00 price target on shares of Johnson & Johnson in a research note on Tuesday, December 31st. Zacks Investment Research upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $158.00 price target on the stock in a research note on Wednesday, December 18th. Morgan Stanley upgraded shares of Johnson & Johnson from an “equal weight” rating to an “overweight” rating and raised their price target for the company from $145.00 to $170.00 in a research note on Tuesday, December 17th. Finally, Wells Fargo & Co raised their price target on shares of Johnson & Johnson from $155.00 to $165.00 and gave the company an “overweight” rating in a research note on Thursday, January 9th. Three research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $159.33.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

See Also: Cost of Goods Sold (COGS)

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

CWM Advisors LLC Decreases Stake in National-Oilwell Varco, Inc.
CWM Advisors LLC Decreases Stake in National-Oilwell Varco, Inc.
CWM Advisors LLC Sells 287 Shares of Watts Water Technologies Inc
CWM Advisors LLC Sells 287 Shares of Watts Water Technologies Inc
James Investment Research Inc. Purchases 1,095 Shares of iShares Russell 1000 Value ETF
James Investment Research Inc. Purchases 1,095 Shares of iShares Russell 1000 Value ETF
James Investment Research Inc. Purchases 46,666 Shares of iShares MSCI South Korea ETF
James Investment Research Inc. Purchases 46,666 Shares of iShares MSCI South Korea ETF
PNM Resources Inc  Shares Sold by James Investment Research Inc.
PNM Resources Inc Shares Sold by James Investment Research Inc.
James Investment Research Inc. Acquires 30,776 Shares of Radian Group Inc
James Investment Research Inc. Acquires 30,776 Shares of Radian Group Inc


© 2006-2020 Ticker Report